ADVERTISEMENT
Abemaciclib, Letrozole Therapy With Recurrent ER-Positive Endometrial Cancer
A phase II study, presented at the 2022 SGO Annual Meeting, evaluated the combination of abemaciclib, a targeted drug, and letrozole, an aromatase inhibitor, among recurrent ER-positive endometrial cancer.
Among the 30 patients included, all had received a median of three prior therapies. Notably, approximately half had been treated with hormonal therapy prior to the trial's commencement.
With a median follow-up of 12.5 months, 75% of the patients had their tumors shrink or become stable. Moreover, approximately 30% of the trial's participants experience tumor shrinkage by more than 30%. The benefits were persistent: the median time before the disease began to worsen was 9.1 months, the investigators reported.
“When we compare the efficacy of this regimen with that of other endocrine therapies for endometrial cancer, we can see this combination is extremely promising,” stated presenting author Panagiotis Konstantinopoulos, MD, PhD, and co-investigators. Moreover, “Our findings suggest it will be a very effective alternate endocrine therapy for patients with recurrent endometrial cancer whose tumors express the estrogen receptor.”
“Based on our findings, the letrozole/abemaciclib combination should be considered worthy of further evaluation for patients with recurrent ER-positive endometrial cancer,” Dr. Konstantinopoulos, alongside fellow investigators, concluded.
